MedTrace Logo

Short-term Metabolic Effects of Mirtazapine in Healthy Subjects

NCT00878540 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2010-09-16

No results posted yet for this study

Summary

The purpose of this study is to determine metabolic changes upon a 7 day medication of 30 mg mirtazapine per day in healthy subjects.

Conditions

  • Healthy

Interventions

DRUG

mirtazapine

30 mg mirtazapine once daily for 7 days

Sponsors & Collaborators

  • Max-Planck-Institute of Psychiatry

    lead OTHER

Principal Investigators

  • Florian Holsboer, MD, PhD · Max Planck Institute of Psychiatry, Munich

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
25 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00878540 on ClinicalTrials.gov